137 related articles for article (PubMed ID: 36633209)
1. Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase.
Martin CE; Kohorst MA; Ferdjallah A; Kalmes JL; Johnson HM; Galardy PJ; Khan SP; Kuhn AK
Pediatr Blood Cancer; 2023 May; 70(5):e30208. PubMed ID: 36633209
[No Abstract] [Full Text] [Related]
2. Hyperammonemia secondary to asparaginase: A case series.
Nussbaum V; Lubcke N; Findlay R
J Oncol Pharm Pract; 2016 Feb; 22(1):161-4. PubMed ID: 25245038
[TBL] [Abstract][Full Text] [Related]
3. Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia.
Lee A; Eldem I; Altintas B; Nguyen H; Willis D; Langley R; Shinawi M
Mol Genet Metab; 2023 Jul; 139(3):107627. PubMed ID: 37327713
[TBL] [Abstract][Full Text] [Related]
4. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Jörck C; Kiess W; Weigel JF; Mütze U; Bierbach U; Beblo S
Pediatr Hematol Oncol; 2011 Feb; 28(1):3-9. PubMed ID: 20615069
[TBL] [Abstract][Full Text] [Related]
5. Hyperinsulinism-induced hypoglycemia secondary to asparaginase Erwinia chrysanthemi (recombinant)-rywn chemotherapy in a pediatric AML patient.
Carlo A; Watson A; Klein G; Ghanny S; Tell S; Horowitz T; Siver M; Appel B; Chen J
Pediatr Blood Cancer; 2024 Apr; 71(4):e30914. PubMed ID: 38321590
[No Abstract] [Full Text] [Related]
6. Multiple Asparaginase Infusions Cause Increasingly Severe Acute Hyperammonemia.
Buddington RK; Buddington KK; Howard SC
Med Sci (Basel); 2022 Aug; 10(3):. PubMed ID: 35997335
[TBL] [Abstract][Full Text] [Related]
7. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
8. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Tong WH; Pieters R; de Groot-Kruseman HA; Hop WC; Boos J; Tissing WJ; van der Sluis IM
Haematologica; 2014 Nov; 99(11):1716-21. PubMed ID: 25150254
[TBL] [Abstract][Full Text] [Related]
9. [Molecular basis of hyperammonemia secondary to asparaginase: from therapeutic efficacity to toxicity].
Gallin M; Damaj L; Gandemer V; Bendavid C; Moreau C
Ann Biol Clin (Paris); 2023 Oct; 81(4):365-377. PubMed ID: 37864442
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
11. Symptomatic Hyperammonemia With Erwinia chrysanthemi-derived Asparaginase in Pediatric Leukemia Patients.
Gossai N; Richards M; Boman L; Messinger Y; Gernbacher S; Perkins J; Bostrom B
J Pediatr Hematol Oncol; 2018 May; 40(4):312-315. PubMed ID: 29334534
[TBL] [Abstract][Full Text] [Related]
12. [Activity of Erwinia-asparaginase after anaphylactic reaction to Peg-asparaginase].
Viña Romero MM; García Gil S; Nazco Casariego GJ; Merino Alonso J; Gutiérrez Nicolás F
An Pediatr (Engl Ed); 2019 Mar; 90(3):187-188. PubMed ID: 29705180
[No Abstract] [Full Text] [Related]
13. Erwinia asparaginase: coming closer to an understanding of its use in pediatric acute lymphoblastic leukemia?
Maloney KW
Pediatr Blood Cancer; 2010 Feb; 54(2):189-90. PubMed ID: 19967774
[No Abstract] [Full Text] [Related]
14. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
[TBL] [Abstract][Full Text] [Related]
15. Asparaginase
Gao C; Ma X; Zhang Z; Lu Q; Ashby CR; Wei L; Chen ZS
Drugs Today (Barc); 2022 Jun; 58(6):261-271. PubMed ID: 35670704
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
17. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
[TBL] [Abstract][Full Text] [Related]
18. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?
Lashkari HP; Lancaster D; Atra A; Champion MP; Taj MM
Int J Hematol; 2011 Dec; 94(6):571-5. PubMed ID: 22057510
[TBL] [Abstract][Full Text] [Related]
20. Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia.
Tong WH; Mesegué M; Dapena JL; Camós M; Rives S
Hematol Oncol; 2022 Oct; 40(4):809-811. PubMed ID: 34961954
[No Abstract] [Full Text] [Related]
[Next] [New Search]